Year: 2020

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC) (OTCQX: ALLXF) announced today that it has commenced a private placement financing with a group of investors principally referred by Aris Gold Corporation (“Aris Gold”) that will result in changes to the management and the board of directors (the “Board”) of the Company, as well as a change in the Company’s name to “Aris Gold Corporation” (the “Aris Transaction”). Once the financing is completed, Gran Colombia Gold Corp. (“Gran Colombia”) is expected to become an approximately 45% shareholder of Caldas Gold and will have the right to nominate two directors to the Caldas Gold Board at completion of the Aris Transaction. Under the financing, the Company has agreed...

FOLSOM, NJ, Nov. 23, 2020 (GLOBE NEWSWIRE) —                                                                                                 Media Contact:  609-561-9000 x4496Media@sjindustries.com                                                                                                          Investor Contact: Dan Fidell(609) 561-9000 ext. 7027dfidell@sjindustries.comFOR IMMEDIATE RELEASESJI Raises Dividend for 22nd Consecutive YearFOLSOM, NJ, November 23, 2020 – SJI (NYSE: SJI) announced today that its board of directors voted to increase the company’s regular quarterly dividend from $0.2950 per share to $0.3025 per share. The new annualized dividend of $1.21 represents an increase of 2.54 percent per share over the previous level.With this announcement, SJI has increased its dividend for 22 consecutive years.Factors the...

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the publication of clinical data that provides molecular insight into TRC102’s mechanism of action and patient populations most likely to respond to treatment. The article, entitled, “Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment,” highlights the clinical features and tumor biology of an exceptional responder patient treated with TRC102 at the National Cancer Institute (NCI): https://www.traconpharma.com/wp-content/uploads/2020/11/Can_Cell_2020_Nov_Mol_Analysis_ER.pdfThe...

WALL, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that it has partnered with Prominic.NET, an owner and operator of data centers serving businesses running on HCL Digital Solutions (formerly IBM Collaboration) products, to deploy BIO-key’s PortalGuard IAM solution to a U.S. DoD agency. PortalGuard will provide enhanced user access security to the agency’s enterprise applications and data via secure smart card authentication.BIO-key implemented its PortalGuard IAM solution on the enterprise-grade HCL Domino-based environment to support application access requirements for the DoD agency’s mission-critical environment. PortalGuard is being used as a Security Assertion Markup Language...

VANCOUVER, British Columbia, Nov. 23, 2020 (GLOBE NEWSWIRE) — FPX Nickel Corp. (FPX-TSX.V) (“FPX Nickel” or the “Company”) announces the resignation of Stuart Harshaw as a director of the Company.   Mr. Harshaw has recently taken on a role as President and CEO of another mining company, limiting his capacity to act on public company boards.“Stuart has been a valuable contributor to FPX Nickel as both an advisor and board member,” commented the Company’s Chairman, Peter Bradshaw. “He has played an important role in helping us to advance our flagship Baptiste Project at the Decar Nickel District, and his contributions have allowed us to deepen our relationships with key strategic players in the nickel market, including offtakers, trading companies and major mining companies. We wish Stuart all the best in his new role and future endeavours.”About...

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Details are as follows:Evercore ISI 3rdAnnual HealthCONx ConferenceDate: Wednesday, December 2Time: 4:45 p.m. ETA live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 90 days following the fireside chat.   About Codiak BioSciencesCodiak is a clinical-stage biopharmaceutical company focused on pioneering the...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV: EMO) is pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation, as co-lead agent and sole bookrunner, along with Clarus Securities Inc. as co-lead agent (together, the “Agents”) in connection with a best efforts, private placement of units of the Company (the “Units”) at a price of $0.14 per Unit (the “Offering Price”) for aggregate gross proceeds of up to $2,500,000 (the “Offering”).Each Unit will be comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall be exercisable to acquire...

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call from 10:00 a.m. to 12:00 p.m. Eastern Time. The call will be concurrently webcast with a slide presentation.The call topics will include:A deep dive into the TB market and how investments made over the past few years have re-positioned the Company to capitalise on what the Company believes is a great long-term growth opportunity. This will include an update on the Company’s automation plans and the role the Company believes...

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment...